Kite Pharma, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Revenues
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Other income (expense), net
Total other income (expense), net
Loss before income taxes
Benefit from income taxes
Net loss
Unrealized loss on available-for-sale securities, net
Foreign currency translation adjustments
Unrealized loss on available-for-sale securities, net
Comprehensive loss
Series A preferred stock dividend
Net loss attributable to common stockholders
Net loss per share, basic and diluted (usd per share)
Weighted-average shares outstanding, basic and diluted (shares)

Comments